Correction to: Immunotherapy Alone or in Combination with Chemotherapy as First-Line Treatment of Non-Small Cell Lung Cancer

被引：0

作者：

Puneet Saxena

Pawan Kumar Singh

Prabhat Singh Malik

Navneet Singh

机构：

[1] Postgraduate Institute of Medical Education and Research (PGIMER),Department of Pulmonary Medicine

[2] University of Health Sciences,Department of Pulmonary and Critical Care Medicine, Post Graduate Institute of Medical Sciences (PGIMS)

[3] All India Institute of Medical Sciences,Department of Medical Oncology, Dr. B.R.A.I.R.C.H

来源：

Current Treatment Options in Oncology | 2020年 / 21卷

关键词：

D O I：

暂无

中图分类号：

学科分类号：

摘要：

The original version of this article unfortunately contained mistakes. In Table 2, under the column 'Lead to death' in Row 5 [CheckMate-026], the figures should read as '0.7' for Experimental Arm and '1.1' for Comparator. Right now, these are printed as 0.007 and 0.011 respectively.

引用

共 50 条

[31] Comparative Efficacy and Safety of Immunotherapy Alone and in Combination With Chemotherapy for Advanced Non-small Cell Lung Cancer
Wang, Xue
Niu, Xiaomin
An, Na
Sun, Yile
Chen, Zhiwei
FRONTIERS IN ONCOLOGY, 2021, 11
[32] First-Line Immunotherapy for Non-Small-Cell Lung Cancer
Reck, Martin
Remon, Jordi
Hellmann, Matthew D.
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06) : 586 - +
[33] Immunotherapy beyond progression following first-line chemotherapy plus immunotherapy in advanced non-small cell lung cancer: A retrospective study
Gu, Xinyue
Hu, Yue
Mungur, Ishanee Devi
Gu, Feifei
Xiong, Ying
Cui, Jin
Zhong, Luhui
Zhang, Kai
Liu, Li
ONCOLOGY LETTERS, 2025, 29 (02)
[34] Immunotherapy combinations and chemotherapy sparing schemes in first line non-small cell lung cancer
Sereno, Maria
Higuera, Oliver
Cruz Castellanos, Patricia
Falagan, Sandra
Mielgo-Rubio, Xabier
Trujillo-Reyes, Juan Carlos
Counago, Felipe
WORLD JOURNAL OF CLINICAL ONCOLOGY, 2021, 12 (12): : 1182 - 1192
[35] Dual-organ toxicity during treatment with nivolumab and ipilimumab in combination with chemotherapy in the first-line treatment of non-small cell lung cancer
Dyzma-Kasprzak, Agnieszka
Kasprzak, Karol
Szczepaniak-Wojtowicz, Elzbieta
Milanowska, Joanna
Chmielewska, Izabela
Krawczyk, Pawel
ONCOLOGY IN CLINICAL PRACTICE, 2024,
[36] First-line immunotherapy in non-small cell lung cancer: how to select and where to go
Mogavero, Andrea
Cantale, Ornella
Mollica, Veronica
Anpalakhan, Shobana
Addeo, Alfredo
Mountzios, Giannis
Friedlaender, Alex
Kanesvaran, Ravindran
Novello, Silvia
Banna, Giuseppe Luigi
EXPERT REVIEW OF RESPIRATORY MEDICINE, 2023, 17 (12) : 1191 - 1206
[37] First-line avelumab in combination with cetuximab and chemotherapy in patients with advanced squamous non-small cell lung cancer (NSCLC)
Andric, Z. G.
Galffy, G.
Cobo Dols, M.
Szima, B.
Stojanovic, G.
Petrovic, M. D.
Felip Font, E.
Vicente Baz, D.
Ponce Aix, S.
Juan-Vidal, O.
Tehenes, S.
Szalai, Z.
Losonczy, G.
Calles Blanco, A.
Bernabe, R.
Duecker, K.
Zhou, D.
Schroeder, A.
Guezel, G.
Ciardiello, F.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (04) : S753 - S754
[38] First-line immune-chemotherapy combination: the right strategy to fight squamous non-small cell lung cancer?
Passiglia, Francesco
Bironzo, Paolo
Scagliotti, Giorgio V.
TRANSLATIONAL LUNG CANCER RESEARCH, 2019, 8 (04) : 546 - 549
[39] The Role of Monoclonal Antibody in Combination with First-Line Chemotherapy in Asian Patients with Advanced Non-Small Cell Lung Cancer
Cho, Byoung Chul
Kim, Joo Hang
Soo, Ross A.
Yang, Chih-Hsin
YONSEI MEDICAL JOURNAL, 2010, 51 (01) : 1 - 8
[40] Chemotherapy plus bevacizumab in the first-line treatment of non-small cell lung cancer: benefits, risks and limitations
F. Grossi
A. Brianti
C. Defferrari
P. Pronzato
memo - Magazine of European Medical Oncology, 2008, 1 (1) : 13 - 16

← 1 2 3 4 5 →